Top-News
Dienstag,
29.03.2016 18:05
von
GlobeNewswire
| Aufrufe: 90
OSE Pharma to attend the Small & Midcap Event in Paris on 11 & 12 April, 2016
Verschiedene Medikamente in Tabletten- und Kapselform. (Symbolbild)
© pixabay.com/CC0
https://pixabay.com
Paris, March 29, 2016, 5:45 PM - OSE Pharma SA (ISIN: FR0012127173; Ticker: OSE), an immuno-oncology company developing a T-specific immunotherapy for late-stage cancer patients, will attend the Small & Midcap Event in Paris on 11 & 12 April, 2016. Located in Pullman Paris Tour Eiffel, this exhibition is dedicated to meetings between listed companies on Euronext markets and institutional investors.
On this occasion, OSE Pharma's management team will meet institutional investors to comment the the company's latest achievements and upcoming news flow, and in particular the company's project of merger with Effimune, a biotech company specialized in immune regulation with clinical applications in autoimmunity, transplantation and immune-oncology, as announced on February 24, 2016.
During the second quarter of 2016, OSE Pharma will also attend following investor and bio-partnering events:
| BIO-Europe Spring® (Stockholm, Sweden) | April 4 - 6, 2016 |
| 2nd Annual Immuno-Oncology: BD&L and Investment Forum (Chicago, USA) | June 3, 2016 |
| ASCO Annual Meeting (Chicago, USA) | June 3-7, 2016 |
| BIO International Convention (San Francisco, USA) | June 6-9, 2016 |
On February 24, 2016, OSE Pharma and Effimune announced proposed merger to create significant immunotherapy player.
The objective of the merger is to create a new international enterprise that offers innovative immunotherapies based on the activation or regulation of the immune system. This new generation of products is optimized to better target key receptors of the activation or regulation of immune response and allow a durable therapeutic effect.
The new company will benefit from a balanced portfolio that would open up major avenues to growth and have a financial visibility of about two years to advance its projects toward greater attractiveness.
ABOUT OSE PHARMA
OSE Pharma is a biotechnology company that designs and develops cancer immunotherapy treatments aimed at re-educating the immune system to fight cancer while preserving patients' quality of life. The Company is conducting a Phase 3 registration trial in Europe and the U.S. for its lead product, Tedopi®, in the treatment of NSCLC.
Tedopi® (OSE-2101) is a new "off-the-shelf" cancer immunotherapy approach based on OSE Pharma's proprietary Memopi® technology. This technology is based on "neo-epitopes" (small synthetic peptides chemically modified to increase the binding the HLA A2 or TCR receptors) which activate a cytotoxic T-cell response and leads the immune system to destroy cancer cells. More than 10,000 epitopes were selected to obtain a therapeutic universal T vaccine.
Tedopi® combines 10 optimized "neo-epitopes" simultaneously acting against 5 tumor-associated antigens (TAAs). These 5 antigens have been selected because they are a factor of poor prognosis in several types of cancers. The 10 "neo-epitopes" have been selected and modified to enhance their binding to HLA-A2 and TCR receptors, and trigger a stronger cytotoxic T-cell response and lead the immune system to destroy cancer cells expressing the HLA-A2 antigen or one of the targeted cancer antigens.
Tedopi® can also be developed in Phase 2 in combination with other immunotherapeutic products or targeted therapies. It is also considered for other oncology indications (ovary, colon, breast) for HLA-A2 positive patients.
OSE Pharma is listed on Euronext Paris (ISIN: FR0012127173; Mnémo: OSE).
For more information, please visit www.osepharma.com
 | |||
 | |||
Follow us on Twitter @OSE_Pharma
Contacts
| OSE Pharma SA Dominique Costantini, CEO dominique.costantini@osepharma.com Mob +33 6 13 20 77 49 Alexis Peyroles, CFO & BD Alexis.peyroles@osepharma.com Mob : +33 6 11 51 19 77 | | Media contacts Citigate Dewe Rogerson Laurence Bault / Lucie Larguier laurence.bault@citigate.fr +33 1 53 32 84 78 Alize RP Florence Portejoie & Caroline Carmagnol osepharma@alizerp.com +33 6 47 38 90 04 Consilium Strategic Communications Chris Gardner / Matthew Neal / Hendrik Thys OSEPharma@consilium-comms.com +44 (0) 20 3709 5700 Rx Communications Group, LLC Melody Carey mcarey@rxir.com + 1 917-322-2571 |
Disclaimer:
This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE PHARMA. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE PHARMA's management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.
Forward-looking statements include statements typically using conditional and containing verbs such as "expect", "anticipate", "believe", "target", "plan", or "estimate", their declensions and conjugations and words of similar import.
Although the OSE PHARMA's management believes that the forward-looking statements and information are reasonable, the OSE PHARMA's shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE PHARMA. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE PHARMA with the AMF. Such forward-looking statements are not guarantees of future performance.
This press release includes only summary information and should be read with the OSE PHARMA Reference Document filed with the AMF on 12 June 2015 under the number R.15-051 as well as the consolidated financial statements and the management report for the fiscal year 2015, available on the OSE PHARMA website.
OSE PHARMA undertakes no obligation to update any forward-looking statements except what would be required by applicable laws and regulations.
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: OSE Pharma Group via Globenewswire
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: OSE Pharma Group via Globenewswire
HUG#1997473
Werbung
Mehr Nachrichten zur Ose Immunotherape Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
-1
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
